CPT code 0031U designates a Proprietary Laboratory Analyses (PLA) test: the Cytochrome P450 1A2 Genotype developed by the Mayo Clinic. As a PLA code, it identifies a single, manufacturer- or laboratory-specific genetic assay that provides genotype information about the CYP1A2 enzyme, which can influence drug metabolism. Nationally, PLA codes like 0031U matter because they standardize billing for novel and proprietary molecular diagnostics, enabling clearer claims processing and payer evaluation for precision medicine services.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find an explanation of what the code represents, the clinical context for a CYP1A2 genotype test, typical service setting and service type, and an outline of payer coverage considerations. The publication also summarizes available benchmarks and policy-relevant updates where provided, and highlights implications for clinical laboratories and billing workflows.

This executive summary presents the code’s purpose, its role in genetic testing reimbursement, and what stakeholders can expect to learn about billing classification, payer engagement, and operational impacts of adopting a PLA-coded laboratory assay.